Distributions of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe.

C-reactive protein (CRP), the classic marker of acute-phase response, is an indicator of a variety of pathologic processes, including infections, tissue damage, and chronic inflammatory diseases (1)(2). The majority of more than 15 well-conducted prospective studies in initially healthy individuals have shown a strong and independent association between concentrations of CRP within the reference interval (<5 mg/L) and future major cardiovascular events (3), although in some of them, no such association could be established (4)(5)(6)(7). The summary estimate of the relative risk in formal metaanalysis was 2.0 (95% confidence interval, 1.6–2.5) (3). Furthermore, CRP has been shown to add to risk prediction beyond and above established cardiovascular risk factors (8). On the basis of data from the Physicians’ Health Study and the Nurses’ Health Study, an algorithm for risk assessment of future coronary events that combines both CRP concentration and the ratio of total cholesterol to HDL-cholesterol has recently been proposed (9). Because atherosclerosis represents a low-grade inflammatory process in the vascular bed, high-sensitivity (hs) assays are needed when using circulating CRP concentrations for risk prediction in cardiovascular diseases. Such assays have been developed and are now commercially available (10)(11). However, before screening of individuals at risk can be recommended, CRP distributions in apparently healthy adults in the general population must be known. Such information is scarce. Furthermore, in previous reports, women using oral contraceptives or receiving hormone replacement therapy (HRT), both of which have been shown to significantly increase CRP concentrations, had not been excluded (12)(13)(14)(15). In this report, we describe the frequency distribution of CRP concentrations in 13 527 adult men and women from different representative populations in Western Europe. Furthermore, for one area [the MONICA (Monitoring Trends and Determinants in …

[1]  K. Tang,et al.  Simultaneous genotyping of seven single-nucleotide polymorphisms in the MDR1 gene by single-tube multiplex minisequencing. , 2003, Clinical chemistry.

[2]  W. Koenig,et al.  C-Reactive Protein Risk Prediction: Low Specificity, High Sensitivity , 2002, Annals of Internal Medicine.

[3]  G. Dagenais,et al.  Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. , 2001, Archives of internal medicine.

[4]  Natalia S. Rost,et al.  Plasma Concentration of C-Reactive Protein and Risk of Ischemic Stroke and Transient Ischemic Attack: The Framingham Study , 2001, Stroke.

[5]  K. Kayaba,et al.  Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population : Jichi Medical School Cohort Study. , 2001, American journal of epidemiology.

[6]  G. Lowe,et al.  C-Reactive Protein, Fibrin D-Dimer, and Incident Ischemic Heart Disease in the Speedwell Study: Are Inflammation and Fibrin Turnover Linked in Pathogenesis? , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[7]  Hermann Brenner,et al.  Effect of alcohol consumption on systemic markers of inflammation , 2001, The Lancet.

[8]  C. Kluft,et al.  Determination of the habitual low blood level of C-reactive protein in individuals. , 2001, Italian heart journal : official journal of the Italian Federation of Cardiology.

[9]  D. Rothenbacher,et al.  Role of novel markers of inflammation in patients with stable coronary heart disease. , 2001, The American journal of cardiology.

[10]  N Rifai,et al.  Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. , 2001, Clinical chemistry.

[11]  W. Koenig,et al.  C-Reactive protein and cardiovascular risk: has the time come for screening the general population? , 2001, Clinical chemistry.

[12]  G. Lowe,et al.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. , 2000, The New England journal of medicine.

[13]  D. Strachan,et al.  C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. , 2000, European heart journal.

[14]  J. Danesh,et al.  Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses , 2000, BMJ : British Medical Journal.

[15]  G. Lowe,et al.  Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. , 2000, Clinical chemistry.

[16]  L. Pilotto.  [Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations]. , 2000, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[17]  L. Bouter,et al.  von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[18]  N Rifai,et al.  Clinical efficacy of an automated high-sensitivity C-reactive protein assay. , 1999, Clinical chemistry.

[19]  A. Döring,et al.  Oral contraceptive use is associated with a systemic acute phase response , 1999 .

[20]  E. Barrett-Connor,et al.  Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. , 1999, Circulation.

[21]  J. Manson,et al.  Hormone replacement therapy and increased plasma concentration of C-reactive protein. , 1999, Circulation.

[22]  C. Stehouwer,et al.  Increased C-reactive Protein Levels during Short-term Hormone Replacement Therapy in Healthy Postmenopausal Women , 1999, Thrombosis and Haemostasis.

[23]  A. Döring,et al.  C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. , 1999, Circulation.

[24]  P. Ridker,et al.  Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. , 1998, Circulation.

[25]  M. Pepys,et al.  Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. , 1998, Clinical chemistry.

[26]  P. Macfarlane,et al.  West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996 .

[27]  D. Strachan,et al.  C Reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study , 1996, BMJ.

[28]  J. Robotham,et al.  The acute-phase response. , 1995, New horizons.

[29]  A. Whitehead,et al.  The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. , 1994, Immunology today.

[30]  P. Minor,et al.  WHO Expert Committee on Biological Standardization. , 2004, World Health Organization technical report series.

[31]  Principal Investigators,et al.  The World Health Organization MONICA project (monitoring trends and determinants in cardiovascular disease): a major international collabaration , 1988 .

[32]  M. Kornitzer,et al.  The World Health Organization MONICA Project (Monitoring trends and determinants in cardiovascular disease): A major international Collaboration , 1988 .

[33]  The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. , 1988, Journal of clinical epidemiology.

[34]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[35]  Laurent Degos,et al.  HISTOCOMPATIBILITY DETERMINANTS IN MULTIPLE SCLEROSIS , 1974 .